Skip to Content
Merck
  • A novel technique to determine an 'apparent ke0 ' value for use with the Marsh pharmacokinetic model for propofol.

A novel technique to determine an 'apparent ke0 ' value for use with the Marsh pharmacokinetic model for propofol.

Anaesthesia (2014-04-18)
A J Thomson, A F Nimmo, F H M Engbers, J B Glen
ABSTRACT

Debate continues over the most appropriate blood-brain equilibration rate constant (ke0) for use with the Marsh pharmacokinetic model for propofol. We aimed to define the optimal ke0 value. Sixty-four patients were sedated with incremental increases in effect-site target concentration of propofol while using six different ke0 values within the range 0.2-1.2 min(-1). Depth of sedation was assessed by measuring visual reaction time. A median 'apparent ke0' value of 0.61 min(-1) (95% CI 0.37-0.78 min(-1)) led to the greatest probability of achieving a stable clinical effect when the effect-site target was fixed at the effect-site concentration displayed by the target-controlled infusion system, at the time when a desired depth of sedation had been reached. By utilising a clinically relevant endpoint to derive this value, inter-individual pharmacokinetic and pharmacodynamic variability may be accounted for.

MATERIALS
Product Number
Brand
Product Description

Propofol, European Pharmacopoeia (EP) Reference Standard
Pricing and availability is not currently available.
Supelco
Propofol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Pricing and availability is not currently available.
Sigma-Aldrich
2,6-Diisopropylphenol, 97%
Pricing and availability is not currently available.